|
rs121913500
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Cancer cells heterozygous for the IDH1(R132H) mutation exhibited less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there were higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells.
|
26363012 |
2015 |
|
rs118101777
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Cancer cells heterozygous for the IDH1(R132H) mutation exhibited less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there were higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells.
|
26363012 |
2015 |
|
rs104893626
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cancer cell fraction analysis in WM and IgM MGUS patients showed CXCR4(S338X) mutations were primarily subclonal, with highly variable clonal distribution (median 35·1%, range 1·2-97·5%).
|
26659815 |
2016 |
|
rs401681
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Cancer susceptibility of the rs401681 polymorphism, located in the TERT-CLPTM1L locus, has been studied in many cancers.
|
29033187 |
2017 |
|
rs1057519895
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cancer-associated arginine mutations in the WD40 domain (R465H, R479Q and R505C) abolish both FBXW7 interaction with PAR and recruitment to DNA damage sites, causing inhibition of XRCC4 polyubiquitination and NHEJ.
|
30722038 |
2019 |
|
rs149680468
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cancer-associated arginine mutations in the WD40 domain (R465H, R479Q and R505C) abolish both FBXW7 interaction with PAR and recruitment to DNA damage sites, causing inhibition of XRCC4 polyubiquitination and NHEJ.
|
30722038 |
2019 |
|
rs200956178
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cancer-associated arginine mutations in the WD40 domain (R465H, R479Q and R505C) abolish both FBXW7 interaction with PAR and recruitment to DNA damage sites, causing inhibition of XRCC4 polyubiquitination and NHEJ.
|
30722038 |
2019 |
|
rs1801282
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study.
|
12609711 |
2003 |
|
rs1805192
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study.
|
12609711 |
2003 |
|
rs28934576
|
|
|
0.100 |
GeneticVariation |
BEFREE |
R273H expression in p53-null cancer cell SK-OV-3 and Saos-2 did not significantly affect cell invasion and migration activities.
|
17636407 |
2007 |
|
rs121913331
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Arg1114X in APC gene, as a hot spot mutation in Chinese CRC, may predispose to the cancer metastasis of sporadic CRC.
|
17653897 |
2007 |
|
rs61754966
|
|
|
0.070 |
GeneticVariation |
BEFREE |
I171V mutation was present in 17 cancer patients compared with only one in healthy individuals.
|
18280732 |
2008 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Arg72Pro SNP of p53 has been associated with many types of cancer as well as with survival and longevity.
|
22116280 |
2011 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Arg72Pro SNP of p53 has been associated with many types of cancer as well as with survival and longevity.
|
22116280 |
2011 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Arg72Pro SNP of p53 has been associated with many types of cancer as well as with survival and longevity.
|
22116280 |
2011 |
|
rs4986791
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Thr399Ile polymorphism was significantly associated with an elevated cancer risk in overall analysis (T allele versus C allele, OR=1.72, 95% CI: 1.27-2.33; TC versus CC, OR=1.63, 95% CI: 1.18-2.26; TT+TC versus CC, OR=1.70, 95% CI: 1.24-2.34) and especially in gastrointestinal subgroup (T allele versus C allele, OR=2.01, 95% CI: 1.40-2.89; TC versus CC, OR=1.86, 95% CI: 1.26-2.74; TT+TC versus CC, OR=1.97, 95% CI: 1.35-2.88).
|
22441122 |
2012 |
|
rs111853599
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Y63H point mutation found to be associated with cancer using SIFT, Polyphen, PhD-SNP, MutPred, CanPredict and Dr. Cancer tools.
|
22974711 |
2013 |
|
rs1285136498
|
|
|
0.020 |
GeneticVariation |
BEFREE |
S100P - low molecular weight acidic protein has been shown to be involved in processes of proliferation, survival, angiogenesis, multidrug resistance and metastasis in various human malignancies.
|
23364898 |
2013 |
|
rs1805010
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results suggest that Q576R, I75V and S503P may be associated with a decreased cancer risk for certain types of cancers and in some specific ethnic groups.
|
23464436 |
2012 |
|
rs1805015
|
|
|
0.020 |
GeneticVariation |
BEFREE |
S503P C allele carriers were also associated with a decreased cancer risk in Asians (CC VS TT: OR = 0.29, 95%CI = 0.08-0.99).
|
23464436 |
2012 |
|
rs4977574
|
|
|
0.010 |
GeneticVariation |
BEFREE |
rs4977574 on chromosome 9p21 was genotyped in 24 777 subjects from the Malmö Diet and Cancer study who were free from CVD prior to the baseline examination.
|
23480785 |
2013 |
|
rs1042522
|
|
|
0.100 |
GeneticVariation |
BEFREE |
R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting.
|
25768405 |
2015 |
|
rs1131691014
|
|
|
0.100 |
GeneticVariation |
BEFREE |
R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting.
|
25768405 |
2015 |
|
rs878854066
|
|
|
0.100 |
GeneticVariation |
BEFREE |
R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting.
|
25768405 |
2015 |
|
rs61764370
|
|
|
0.050 |
GeneticVariation |
BEFREE |
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers.
|
25940428 |
2016 |